Story perspectives

FDA Plans to Cut Expert Panels, Sparks Transparency Concerns

9/12/2025

50 11

Summary

Story summary

FDA leaders under President Trump plan to eliminate expert advisory panels for drug applications, citing redundancy and workload issues.
George Tidmarsh, head of the FDA’s Center for Drug Evaluation and Research, claims these panels are unnecessary for specific drug reviews.
Critics warn that this move diminishes public scrutiny and expert input in FDA decisions.
Former officials stress the value of advisory committees for informed decision-making.
The FDA has conducted fewer advisory meetings since Trump’s return, raising transparency concerns.

1 of 1

Story summary

FDA leaders under President Trump plan to eliminate expert advisory panels for drug applications, citing redundancy and workload issues.
George Tidmarsh, head of the FDA’s Center for Drug Evaluation and Research, claims these panels are unnecessary for specific drug reviews.
Critics warn that this move diminishes public scrutiny and expert input in FDA decisions.
Former officials stress the value of advisory committees for informed decision-making.
The FDA has conducted fewer advisory meetings since Trump’s return, raising transparency concerns.